Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
US specialty drugmaker Pernix Therapeutics (NYSE: PTX) has entered into a definitive agreement to acquire privately-held Cypress Pharmaceuticals, a maker of generic drugs, and its subsidiary Hawthorn Pharmaceuticals, which markets branded medicines. 15 November 2012
Generics
Shares in Russian companies 36.6 and Veropharm surged in Monday afternoon trading on the Moscow Stock Exchange on news the competition watchdog, the FAS, had cleared financial conglomerate AFK Sistema to buy up to 100% of drugmaker Veropharm, as had previously been mooted (The Pharma Letter November 6). 14 November 2012
Generics
AFK Sistema, the financial conglomerate owned by the Russian billionaire Vladimir Yevtushenko, is considering acquiring Veropharm, Russia's third largest drugmaker from its current owner "36.6," a local drug-store chain. The transaction cost has been estimated at between 4.9 and 5.7 billion roubles ($150-$180 million). 6 November 2012
Generics
US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based pharma firm moksha8 that will provide Forest with a commercial footprint in Latin America and give moksha8 access to the antidepressant Viibryd (vilazodone) and potentially other Forest products for the Latin American market. 24 October 2012
Generics
Global drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that it is prepared to pay up to $680 million to acquire USA-based, privately-held NextWave Pharmaceuticals, which is focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders. 23 October 2012
Generics
India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) announced this morning that it intendeds to make a public offer to acquire the issued and outstanding shares of Netherlands-based drug delivery technology firm OctoPlus NV (Euronext Amsterdam: OCTO) for 27.39 million euros ($35.7 million; cum dividend), or 0.52 euros a share, in cash, representing 100% of the issued and outstanding ordinary shares. 22 October 2012
Generics
Privately-held US drugmaker Alvogen last Friday entered into an agreement to acquire a majority share in South Korea-based generic drugs manufacturer and marketer Kunwha Pharmaceuticals through a combination of new shares issued by Kunwha to Alvogen and the acquisition of shares owned by Hongsun Chang, Kunwha's chairman and related parties. Financial terms of the transaction were not disclosed. 21 October 2012
Generics
Following speculation that started last month, India's SMS Pharmaceuticals this week confirmed that it has sold its manufacturing units in Visakhapatnam, Andhra Pradesh, to US generic drugmaker Mylan Laboratories (Nasdaq: MYL) for 1.73 billion rupees ($33 million), said the company in a filing, reported by VCCircle. The unit is involved in manufacturing bulk drugs and formulations in the oncology segment. 18 October 2012
Generics
The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic drugmaker Actavis to sell the rights and assets to 18 drugs to Sandoz International (the generics unit of Novartis) and US firm Par Pharmaceuticals, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson's proposed $5.9 billion acquisition of Actavis (The Pharma Letter April 26) would otherwise be anticompetitive. Watson has agreed to make the divestments. 16 October 2012
Generics
Channel Islands-based private equity firm Cinven has reached agreement to acquire UK-based niche generic drugmaker Amdipharm from Vijay and Bhikhu Patel, the Indian billionaires behind Waymade, the global pharmaceutical company, in a deal valuing Amdipharm at £367 million ($590.4 million). 15 October 2012
Generics
USA-based BioSante Pharmaceuticals (Nasdaq: BPAX) and privately-held specialty and generic drugmaker ANI Pharmaceuticals have entered into a definitive all-stock merger agreement. The transaction has been approved by the boards of directors of both companies and is currently expected to close in the first quarter of 2013, subject to customary closing conditions. 5 October 2012
Generics
Par Pharmaceuticals (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals, and US private equity group TPG have announced the completion of Par's acquisition by certain affiliates of TPG for a consideration of $1.9 billion (The Pharma Letter July 17). 1 October 2012
Generics
Mallinckrodt, the soon to be spun-out pharmaceuticals business of Ireland-based Covidien (NYSE: COV), has signed a definitive agreement to acquire CNS Therapeutics, a privately held specialty pharmaceutical company for around $100 million. 25 September 2012
Generics
Global drugs behemoth Pfizer (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading Chinese pharmaceutical company, have announced the launch of Hisun-Pfizer Pharmaceuticals Co), a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. This furthers the companies' earlier framework agreements (The Pharma Letter February 19). 14 September 2012
Generics
Cinven, a Channel Islands-based private equity firm, said last Friday that it has reached agreement to acquire UK specialty drugmaker Mercury Pharma, as a platform for further industry consolidation, from Hg Capital for an enterprise value of £465 million ($730 million). 20 August 2012
Generics
Leading drug multinationals, including global behemoth Pfizer (NYSE: PFE) and Swiss major Novartis (NOVN: VX) are reportedly considering acquiring India-based Strides Arcolab's injectable drugs business Agila Specialties, according to a report by the Economic Times of India, quoting sources familiar with the situation. 20 August 2012
Generics
German drugmaker Stada Arzneimittel (SAZ: GR) revealed this week that it has signed a contract and accompanying temporary service contracts on the sale of two Russian production facilities, a move that has been anticipated since the company declared its intention to optimize operations in Russia earlier this year (The Pharma Letter April 23). 16 August 2012
Generics
Indian drugmaker Sun Pharmaceutical Industries (SUN: BO) says that it has now reached agreement to acquire Israel-based Taro Pharmaceutical Industries (PinkSheets: TAROF), after the former increased its offer price. 14 August 2012
Generics
Italian drugmaker Recordati (RC: MI) said yesterday that it has signed an agreement to acquire 100% of the share capital of Farma-Projekt Sp zoo, a Polish pharmaceutical company with headquarters in Krakow. 3 August 2012
Generics
The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis (NOVN: VX) to give up its marketing rights to four topical skin care products, under a proposed settlement resolving charges that the company's acquisition of private equity-owned generics firm Fougera Holdings would harm competition in the market for these topical drugs. 17 July 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze